With respect to the indications that we are pursuing , the MARINE study is targeting an indication for which only one other Omega-3 based drug is approved in the US . � � That drug , Lovaza , has worldwide revenues which have been growing rapidly and have now reached nearly $ 1 billion per year . � � The ANCHOR study is targeting an indication for which there is currently no prescription omega-3 drug approved in the US . � � By some estimates , the patient population for this indication is many times larger than the patient population being targeted by the MARINE study .